Results 161 to 170 of about 99,595 (215)

Neutrophil extracellular traps induced by activated platelets as a cause of neutrophil–platelet aggregation in β‐thalassaemia/haemoglobin E patients

open access: yesBritish Journal of Haematology, EarlyView.
Abnormal neutrophils and platelets in splenectomised β‐thalassaemia/haemoglobin E (HbE) disease contribute to neutrophil–platelet aggregation, leading to a high risk of thrombus formation. Activated platelets induce neutrophils to generate neutrophil extracellular trap (NETs) via the P‐selectin–P‐selectin glycoprotein ligand‐1 (PSGL1) pathway, which ...
Rattanawan Thubthed   +11 more
wiley   +1 more source

Clinical and immunological effects of adding cyclophosphamide to pomalidomide–dexamethasone in relapsed‐refractory multiple myeloma: The randomized MUKseven trial

open access: yesBritish Journal of Haematology, EarlyView.
Summary There is an ongoing need for accessible combination therapies for patients with relapsed‐refractory multiple myeloma (RRMM), alongside a growing interest in understanding their immunological effects, particularly on T‐cell populations. Myeloma UK (MUK) MUKseven (NCT02406222) was an academic, UK multicentre randomized controlled, open‐label ...
Andrew Hall   +14 more
wiley   +1 more source

Methaemoglobinaemia: From pathophysiology to contemporary clinical management

open access: yesBritish Journal of Haematology, EarlyView.
Summary Methaemoglobin (MetHb) is an oxidised form of haemoglobin (Hb) unable to bind oxygen. Raised levels of MetHb reduce the blood's oxygen‐carrying capacity, causing potentially severe hypoxaemia and possible death. The condition arises from three main pathologies: mutations in globin genes causing Haemoglobin‐M, inherited deficiency of the enzyme ...
Alexander J. Twine, David C. Rees
wiley   +1 more source

Haemostatic changes and bleeding with anti‐IL‐6 directed therapy in autoimmune diseases

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Anti‐IL‐6 directed therapy, especially tocilizumab (TCZ), is widely used for the treatment of autoimmune diseases such as rheumatoid arthritis, giant cell arteritis and systemic juvenile idiopathic arthritis. Next to being a master regulator of inflammation, IL‐6 also is an important regulator of haemostasis. Although generally well tolerated,
Charlotte D. C. C. van der Heijden   +3 more
wiley   +1 more source

An acute transfusion reaction. [PDF]

open access: yesClin Med (Lond), 2018
Webb C, Norris A, Hands K.
europepmc   +1 more source

Lack of association between vaccine‐induced immune thrombocytopenia and thrombosis and HLA loci in a large cohort

open access: yes
British Journal of Haematology, EarlyView.
Linda Schönborn   +7 more
wiley   +1 more source

Safer Access With Fewer Transfusions: Revisiting Platelet Thresholds in Pediatric Central Venous Catheterization

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Background Central venous catheters (CVCs) are essential in pediatric hematology‐oncology, for the administration of chemotherapy and supportive therapy. Thrombocytopenia increases the risk of bleeding and current guidelines recommend prophylactic platelet transfusions below 40–50 × 109/L, though evidence is limited and transfusions entail ...
Alessandro Raffaele   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy